Treatment with indigo naturalis (IN) is effective in treating ulcerative colitis (UC) and inducing clinical response and mucosal healing, even in patients with steroid-dependent disease or anti–TNF-α refractoriness.
Guidelines and common practice support the role of reactive-based dose optimization at the time of loss of response in patients with IBD being treated with biologics.
In patients with inflammatory bowel diseases (IBD) who underwent colonoscopic surveillance for colorectal neoplasia (CRN), indefinite dysplasia was independently associated with a significant increase in advanced CRN risk.
Researchers compared patient characteristics, patterns of medication use, and comorbidities among elderly and younger patients with inflammatory bowel disease.
For both patients with ulcerative colitis and those with Crohn disease, psychiatric diagnoses were more common in those who were elderly (greater than 65 years old), women, and white, and those with psychiatric conditions more frequently had a history of alcohol abuse, tobacco and substance abuse, personality disorder, and corticosteroid use.
The Food and Drug Administration (FDA) has approved Stelara (ustekinumab; Janssen) for the treatment of adult patients with moderately to severely active ulcerative colitis.
Researchers concluded that fecal tests like FCP do not appear to be affected by physiological changes that occur during pregnancy and that these tests may be useful in predicting IBD activity across all gestational periods, including conception.
Having a mother with a diagnosis of inflammatory bowel disease (IBD), being in the highest socioeconomic quintile at birth, and having an infection in the first year of life increases the risk of developing IBD.
In the phase 3b VARSITY study, patients were randomized to receive either vedolizumab intravenous and placebo subcutaneous, or adalimumab SC and placebo.
There was a significant improvement with supplementation of vitamin D in all inflammatory parameters, including clinical, endoscopic, histopathologic, and serum and fecal markers of inflammation.
Cobitolimod is a first in class, toll-like receptor 9 (TLR9) agonist with local anti-inflammatory effects in the large intestine, which may promote mucosal healing.
The association between disease activity and emotional processing biases may play a role in the higher rates of depression in patients with inflammatory bowel disease.
Smoking is not associated with a beneficial impact in disease outcomes in UC. Furthermore, we found no evidence that smoking cessation impacts adversely on subsequent clinical outcomes.
In terms of benefit and risk, biologics were both considered more beneficial and riskier than immunomodulators. Bowel resection was considered to be slightly more risky, but more beneficial than biologic treatment.
Crohn disease and ulcerative colitis comprise the 2 primary subtypes of inflammatory bowel diseases (IBD). IBD currently has no known cure and whose pathogenesis is not well understood. However, an increasing amount of research points to genetic risk factors combined with antibiotic use and changes in intestinal microbiota as triggers for the onset of IBD.1,2…
JAK inhibitors effectively induce clinical remission in patients with Crohn disease and clinical and endoscopic remission in patients with ulcerative colitis.
